

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of August 2018**

Commission File Number: **001-32001**

**Aptose Biosciences Inc.**

(Translation of registrant's name into English)

251 Consumers Road, Suite 1105 Toronto, Ontario M2J 4R3 Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [  ] Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

On August 29, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) [Exhibit 99.1](#). Press release dated August 29, 2018

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Aptose Biosciences Inc.**  
(Registrant)

Date: August 29, 2018

/s/ Gregory K. Chow  
Gregory K. Chow  
Senior Vice President and Chief Financial Officer

## Aptose to Present at Upcoming Investor Conferences in September 2018

SAN DIEGO and TORONTO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at upcoming conferences:

- **B. Riley FBR Annual Healthcare Conference**

Date: Tuesday, September 4, 2018  
Location: New York Marriott East Side

Dr. Rice will be participating on two panels:

- 9:50 a.m. EDT - *A Beginner's Guide to Blood Cancers*
- 3:25 p.m. EDT - *Immuno-oncology Has Made TKIs Obsolete*

- **H.C. Wainwright & Co. 20<sup>th</sup> Annual Global Investment Conference**

Date: Wednesday, September 5, 2018  
Time: 8:45 a.m. EDT  
Location: The St. Regis New York  
Live webcast: Webcast Link

- **2018 Healthcare Capital and Connections Summit**

Date: September 12-13, 2018  
Location: Andaz Xintiandi, Shanghai, People's Republic of China

The webcast can also be accessed through the Aptose website at [www.aptose.com](http://www.aptose.com) and will be archived shortly after the live event and available for 90 days.

### About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor expected to reach IND submission by the end of 2018 and is planned for development to treat AML and certain B cell malignancies. For further information, please visit [www.aptose.com](http://www.aptose.com).

For further information, please contact:

#### Aptose Biosciences

Greg Chow, CFO  
647-479-9828  
[gchow@aptose.com](mailto:gchow@aptose.com)

#### SMP Communications

Susan Pietropaolo  
201-923-2049  
[susan@smpcommunications.com](mailto:susan@smpcommunications.com)

#### LifeSci Advisors

Michael Wood  
Managing Director  
646-597-6983  
[mwood@lifesciadvisors.com](mailto:mwood@lifesciadvisors.com)